Cargando…
The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis
BACKGROUND: Advanced triple-negative breast cancer (aTNBC) has a poor prognosis; thus, there is a need to identify novel biomarkers to guide future research and improve clinical outcomes. OBJECTIVES: We tested the prognostic ability of an emerging, complete blood count (CBC)-based inflammatory bioma...
Autores principales: | Provenzano, Leonardo, Lobefaro, Riccardo, Ligorio, Francesca, Zattarin, Emma, Zambelli, Luca, Sposetti, Caterina, Presti, Daniele, Montelatici, Giulia, Ficchì, Angela, Martinetti, Antonia, Arata, Alessio, Del Vecchio, Marta, Lauria Pantano, Claudia, Formisano, Barbara, Bianchi, Giulia Valeria, Capri, Giuseppe, de Braud, Filippo, Vernieri, Claudio, Fucà, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102956/ https://www.ncbi.nlm.nih.gov/pubmed/37063779 http://dx.doi.org/10.1177/17588359231165978 |
Ejemplares similares
-
The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab
por: Ligorio, Francesca, et al.
Publicado: (2021) -
Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications
por: Ligorio, Francesca, et al.
Publicado: (2022) -
Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin
por: Zattarin, Emma, et al.
Publicado: (2022) -
Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients
por: Ligorio, Francesca, et al.
Publicado: (2021) -
Risk assessment of thromboembolic events in hospitalized cancer patients
por: Nichetti, Federico, et al.
Publicado: (2021)